{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:43:00Z","timestamp":1789497780143,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>Sugammadex is a novel agent for reversal of steroidal neuromuscular blocking agents (NMBAs) with potential advantages over acetylcholinesterase inhibitors. In preclinical trials, there have been rare instances of bradycardia with progression to cardiac arrest. To better define this issue, its incidence and mitigating factors, we prospectively evaluated the incidence of bradycardia after sugammadex administration in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>Patients \u2265 18 years of age who received sugammadex were included in this prospective, open label trial. After administration, heart rate (HR) was continuously monitored. HR was recorded every minute for 15 minutes and then every five minutes for the next 15 minutes or until patient was transferred out of the operating room. Bradycardia was defined as HR less than 60 beats\/minute (bpm) or decrease in HR by \u2265 10 beats per minute (bpm) if the baseline HR was &lt;70 bpm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study cohort included 200 patients. Bradycardia was observed in 13 cases (7%; 95% confidence interval: 4, 11), occurring a median of 4 minutes after sugammadex administration (IQR: 4, 9, range: 2-25). Among patients developing bradycardia, two (15%) had cardiac comorbid conditions. One patient received treatment for bradycardia with ephedrine. No clinically significant blood pressure changes were noted. On bivariate analysis, patients receiving a higher initial sugammadex dose were more likely to develop bradycardia. On multivariable logistic regression, initial sugammadex dose was not associated with the risk of bradycardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The incidence of bradycardia after administration of sugammadex in our study was low and not associated with significant hemodynamic changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joacp.joacp_346_19","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T07:20:28Z","timestamp":1610954428000},"page":"465-469","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Decrease in heart rate following the administration of sugammadex in adults"],"prefix":"10.4103","volume":"36","author":[{"given":"Trent","family":"Sims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Hakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Tumin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Tobias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20260203","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/pan.13050","article-title":"Current evidence for the use of sugammadex in children","volume":"27","author":"Tobias","year":"2017","journal-title":"Paediatr Anaesth"},{"key":"R2-6-20260203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0034-7094(11)70019-8","article-title":"Assessment of neuromuscular blockade in children at the time of block reversal and the removal of the endotracheal tube","volume":"61","author":"de Souza","year":"2011","journal-title":"Rev Bras Anestesiol"},{"key":"R3-6-20260203","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1460-9592.2010.03335.x","article-title":"Neuromuscular block and current treatment strategies for its reversal in children","volume":"20","author":"Meretoja","year":"2010","journal-title":"Paediatr Anaesth"},{"key":"R4-6-20260203","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcrc.2008.10.010","article-title":"Preclinical pharmacology of sugammadex","volume":"24","author":"Bom","year":"2009","journal-title":"J Crit Care"},{"key":"R5-6-20260203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/bja\/ael158","article-title":"The doughnut and the hole: A new pharmacological concept for anaesthetists","volume":"97","author":"Hunter","year":"2006","journal-title":"Br J Anaesth"},{"key":"R6-6-20260203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/bja\/aem402","article-title":"Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers","volume":"100","author":"Cammu","year":"2008","journal-title":"Br J Anaesth"},{"key":"R7-6-20260203","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/00000542-200510000-00007","article-title":"First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide","volume":"103","author":"Gijsenbergh","year":"2005","journal-title":"Anesthesiology"},{"key":"R8-6-20260203","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00000542-200604000-00009","article-title":"Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study","volume":"104","author":"Sorgenfrei","year":"2006","journal-title":"Anesthesiology"},{"key":"R9-6-20260203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinane.2016.06.018","article-title":"Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: A meta-analysis of randomized controlled trials","volume":"35","author":"Carron","year":"2016","journal-title":"J Clin Anesth"},{"key":"R10-6-20260203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jclinane.2014.08.010","article-title":"Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: A randomized, blinded trial","volume":"27","author":"Koyuncu","year":"2015","journal-title":"J Clin Anesth"},{"key":"R11-6-20260203","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/anae.14160","article-title":"The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis","volume":"73","author":"Hristovska","year":"2018","journal-title":"Anaesthesia"},{"key":"R12-6-20260203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcrc.2008.08.003","article-title":"Clinical limitations of acetylcholinesterase antagonists","volume":"24","author":"Caldwell","year":"2009","journal-title":"J Crit Care"},{"key":"R13-6-20260203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00000542-200502000-00005","article-title":"Impact of anesthesia management characteristics on severe morbidity and mortality","volume":"102","author":"Arbous","year":"2005","journal-title":"Anesthesiology"},{"key":"R14-6-20260203","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1213\/01.ane.0000255645.64583.e8","article-title":"Sugammadex: An opportunity to change the practice of anesthesiology?","volume":"104","author":"Miller","year":"2007","journal-title":"Anesth Analg"},{"key":"R15-6-20260203","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.27.8.1181","article-title":"Sugammadex: A novel agent for the reversal of neuromuscular blockade","volume":"27","author":"Nicholson","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R16-6-20260203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bja.2018.03.003","article-title":"Sugammadex-induced bradycardia and asystole: How great is the risk?","volume":"121","author":"Hunter","year":"2018","journal-title":"Br J Anaesth"},{"key":"R17-6-20260203","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4097\/kjae.2016.69.5.514","article-title":"Cardiac arrest after sugammadex administration in a patient with variant angina: A case report","volume":"69","author":"Ko","year":"2016","journal-title":"Korean J Anesthesiol"},{"key":"R18-6-20260203","first-page":"378","article-title":"Bradycardia in a pediatric heart transplant recipient: Is it the sugammadex?","volume":"22","author":"King","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R19-6-20260203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5455\/ijmsph.2013.251220131","article-title":"Sugammadex associated persistent bradycardia","volume":"3","author":"Bilgi","year":"2014","journal-title":"Inter J Med Sci Pub Health"},{"key":"R20-6-20260203","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1213\/XAA.0000000000000834","article-title":"Profound bradycardia and cardiac arrest after sugammadex administration in a previously healthy patient: A Case Report","volume":"12","author":"Sanoja","year":"2019","journal-title":"A A Pract"},{"key":"R21-6-20260203","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/ALN.0b013e3181f4182a","article-title":"Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block","volume":"113","author":"Schaller","year":"2010","journal-title":"Anesthesiology"},{"key":"R22-6-20260203","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/ALN.0b013e31818a3fee","article-title":"Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine","volume":"109","author":"Jones","year":"2008","journal-title":"Anesthesiology"},{"key":"R23-6-20260203","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2044.2008.05872.x","article-title":"Clinical implications of sugammadex","volume":"64","author":"Caldwell","year":"2009","journal-title":"Anaesthesia"}],"container-title":["Journal of Anaesthesiology Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joacp.JOACP_346_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:35Z","timestamp":1786735775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joacp.JOACP_346_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/joacp.joacp_346_19","relation":{},"ISSN":["0970-9185"],"issn-type":[{"value":"0970-9185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}